de Liaño Lista AG, van Dijk N, de Velasco Oria de Rueda G, et al. - This study was carried out to analyze the outcome of urothelial carcinoma (UC) individuals who received subsequent systemic treatment (SST) and no SST after progressing to immune checkpoint inhibitors (ICIs). Researchers performed a retrospective analysis of UC individuals progressing to frontline or later-line anti–PD-1/PD-L1 therapy in 10 European institutions between March 2013 and September 2017. This study included a sum of 270 UC individuals with PD to ICIs (69 frontline, 201 later line). Overall survival (OS) was investigated with a Kaplan-Meier model. For multivariate analysis (MV), cox regression was applied. The results of this study indicated that individuals progressing to frontline ICIs are at risk of early death, excluding them from experiencing potential benefit from chemotherapy